Here you will find our latest and archived news science 2009 in chronologically order as well as scientific publications.
For all media enquieries please contact Katja Woestenhemke (see contact details on the right).
++ Latest news ++
AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients
AiCuris gewinnt ALLICENSETM 2013 Breakthrough Alliance Award
AiCuris nominated for: Deloitte Recap ALLICENSE 2013 "Breakthrough Alliance Award"
AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial for Herpes Drug Pritelivir
After license deal for letermovir: Head-to-head phase 2 trial initiated by AiCuris to demonstrate superiority of its novel drug pritelivir vs. valacyclovir for treatment of genital herpes
AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus
AiCuris promising drugs against Herpes simplex (AIC316) and Human Cytomegalovirus (Letermovir, AIC246) in preparation for phase III:
Key note at International Herpesvirus Workshop Calgary, Canada
Thomas Goldner gets Philipp Klee Price for his publication "The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase."